November 26, 2025 — Leads & Copy — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) has announced a binding Letter of Intent (LOI) to acquire the cardiology practices of Dr. Roberto Manuel Fernandez-de-Castro and Dr. Hector Rosario Figueroa, two interventional cardiologists in the Dominican Republic.
According to a news release, Hemostemix will acquire the practices for 2,000,000 shares each, subject to adjustment and approval by the TSXV. The company’s strategy involves acquiring accretive medical practices and incorporating its ACP-01 treatments.
The acquisition marks the beginning of Hemostemix’s long-term strategy to acquire profitable, accretive medical practices where it can add ACP-01 treatments. The company’s operations strategy will focus on patient treatment flow, while its sales team aims to leverage practitioner-to-practitioner dialogue to increase the number of practitioners using ACP-01.
Combined, Dr. Fernandez-de-Castro and Dr. Rosario Figueroa have treated more than 200 patients with ACP-01, making them among the most experienced ACP-01 clinicians globally. As pioneers in treating end-stage no-option CVD patients, they can credibly attest to the safety, feasibility, clinical relevancy, and observed efficacy of ACP-01 to patients, referring physicians, hospital partners, and regulators.
Their expertise includes Angina, Ischemic and Dilated Cardiomyopathy, Congestive Heart Failure, Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia, and Vascular Dementia.
Under the terms of the LOI, Dr. Roberto Fernandez-de-Castro and Dr. Rosario Figueroa will contribute medical expertise in cardiovascular disease treatments, actively participate in the clinical implementation of ACP-01 therapy within the Dominican Republic and the Bahamas, facilitate regulatory approvals with Dominican Republic health authorities, and sell their existing medical practices to HEM in exchange for the issuance of 2,000,000 common shares each.
The integration of these practices will commence Hemostemix clinical infrastructure, accelerate ACP-01 commercialization, and provide the foundation for future clinical trial expansion. It will provide a turnkey profit structure that enables hands-on care and follow-up with ACP-01 recipients, which is a significant contributor to improved health outcomes.
Hemostemix intends to replicate this model across additional markets, including Florida, Puerto Rico, and Canada.
Thomas Smeenk, CEO, stated that the acquisition is a transformational milestone for Hemostemix. He said Drs. Fernandez-de-Castro and Rosario Figueroa are world-class cardiologists who have successfully treated 200 ACP-01 patients and that their experience and clinical conviction provide a foundation for accelerating ACP-01 in North America.
The TSXV has approved an extension to December 1st of the terms of the non brokered private placement of Units at $0.11 as announced on October 8, 2025, and as updated November 4, 2025. The Company raised aggregate gross proceeds of $461,230 through the issuance of 4,193,000 units (“Units”) at a price of $0.11 per Unit, to-date. Each Unit consists of one common share in the capital of the Company (a “Common Share”) and one common share purchase warrant (a “Warrant”). Each full Warrant entitles the holder to acquire one additional Common Share at a price of $0.15 per share for a period of two (2) years from the closing date of the Offering, subject to the accelerated expiry provision described as follows. If, on any 10 consecutive trading days occurring after four months and one day has elapsed following the closing date, the closing sales price of the Common Shares (or the closing bid, if no sales were reported on a trading day) as quoted on the TSX Venture Exchange (the “Exchange”) is greater than a weighted average price of $0.185 per Common Share, the Company may provide notice in writing to the holders of the Warrants by issuance of a press release that the expiry date of the Warrants will be accelerated to the date that is 30 days following such press release.
Hemostemix is an autologous stem cell therapy platform company founded in 2003. It has developed, patented, is scaling and selling its blood-based stem cell therapy, VesCell™ (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published results in eleven peer-reviewed publications. ACP-01 is considered a safe and clinically relevant treatment for several conditions, including peripheral arterial disease, chronic limb threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina.
Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five-year mortality rate of 50% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result.
For further information, please contact: Thomas Smeenk, President, CEO EM: tsmeenk@hemostemix.com / PH: 905-580-4170
Source: Hemostemix Inc.
